Quick Takeaways
- ATYR - aTYR PHARMA INC has 10 insiders with reported activity on this page.
- Net insider value flow over the last year: -$6,267.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 10 Insiders of aTYR PHARMA INC
- Symbol
- ATYR on Nasdaq
- Location
- San Diego, CA
What Changed
- Buy value: ; sell value: $6,267.
- Net share flow: -6,421.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$6,267.
Buys
$0
Shares: 0
Insiders: 0
Sells
$6,267
Shares: 6,421
Insiders: 3
Net
-$6,267
Shares: -6,421
Insiders: -3
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 6,421 | $0 | $6,267 | -$6,267 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
aTYR PHARMA INC executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Paul Schimmel | Director | $7,479,261 | Mixed | 08 Oct 2025 | ||
| Sanjay Shukla | President and CEO, Director | $189,085 | -$3,655 | -1.9% | Mixed | 03 Feb 2026 |
| Timothy Coughlin | Director | $98,000 | Filing P/S | 01 May 2025 | ||
| Jill Marie Broadfoot | Chief Financial Officer | $50,575 | -$1,521 | -2.9% | Mixed | 03 Feb 2026 |
| Nancy E. Denyes | General Counsel | $42,489 | -$1,091 | -2.5% | Mixed | 03 Feb 2026 |
| Jane A. Gross | Director | $39,000 | Filing P/S | 01 May 2025 | ||
| Eric Benevich | Director | Mixed | 01 May 2025 | |||
| Sara Zaknoen | Director | Mixed | 01 May 2025 | |||
| Svetlana Lucas | Director | Mixed | 01 May 2025 | |||
| John K. Clarke | Director | Mixed | 22 May 2024 |
Top shareholders of aTYR PHARMA INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FEDERATED HERMES, INC. |
13D/G
13F
|
Company |
11%
|
10,544,437
|
$55,463,739 | -$21,682,577 | 30 Sep 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
6.5%
|
5,763,606
|
$29,221,482 | $0 | 30 Jun 2025 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
1.1%
|
1,039,080
|
$13,601,557 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
15%
|
14,697,995
|
$11,510,000 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13D/G
|
— |
3.2%
|
2,845,354
|
$9,617,297 | $0 | 31 Mar 2025 | |
| Paul Schimmel |
3/4/5
|
Director |
—
mixed-class rows
|
1,471,913
mixed-class rows
|
$7,479,261 | — | 08 Oct 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.1%
|
4,961,871
|
$3,885,145 | — | 31 Dec 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
2.7%
|
2,630,638
|
$2,060,000 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.3%
|
2,283,717
|
$1,788,716 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.8%
|
1,724,843
|
$1,350,725 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
1.7%
|
1,625,297
|
$1,272,607 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.4%
|
1,403,009
|
$1,098,696 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.86%
|
841,350
|
$658,861 | — | 31 Dec 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.79%
|
769,820
|
$602,847 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.78%
|
764,743
|
$598,870 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.72%
|
702,186
|
$549,882 | — | 31 Dec 2025 | |
| Tikvah Management LLC |
13F
|
Company |
0.47%
|
460,833
|
$360,878 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.46%
|
454,443
|
$355,874 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.35%
|
345,587
|
$270,629 | — | 31 Dec 2025 | |
| Sanjay Shukla |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
1,653,553
mixed-class rows
|
$189,085 | -$3,655 | 03 Feb 2026 | |
| Nuveen, LLC |
13F
|
Company |
0.23%
|
227,941
|
$178,500 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.23%
|
221,767
|
$173,666 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.2%
|
193,532
|
$151,555 | — | 31 Dec 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.19%
|
191,048
|
$149,610 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.19%
|
188,149
|
$147,339 | — | 31 Dec 2025 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.19%
|
181,966
|
$142,498 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.18%
|
174,182
|
$136,402 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.13%
|
126,700
|
$99,206 | — | 31 Dec 2025 | |
| Timothy Coughlin |
3/4/5
|
Director |
—
mixed-class rows
|
106,000
mixed-class rows
|
$98,000 | — | 01 May 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.12%
|
120,341
|
$93,866 | — | 31 Dec 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.12%
|
116,717
|
$91,401 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.11%
|
110,373
|
$86,432 | — | 31 Dec 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.1%
|
99,762
|
$78,104 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.1%
|
97,497
|
$76,210 | — | 31 Dec 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.08%
|
79,365
|
$62,151 | — | 31 Dec 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.08%
|
78,953
|
$62,000 | — | 31 Dec 2025 | |
| Jill Marie Broadfoot |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
449,796
mixed-class rows
|
$50,575 | -$1,521 | 03 Feb 2026 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.07%
|
64,480
|
$50,494 | — | 31 Dec 2025 | |
| Nancy E. Denyes |
3/4/5
|
General Counsel |
—
mixed-class rows
|
445,624
mixed-class rows
|
$42,489 | -$1,091 | 03 Feb 2026 | |
| KINGSWOOD WEALTH ADVISORS, LLC |
13F
|
Company |
0.05%
|
52,000
|
$40,721 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.05%
|
50,685
|
$39,691 | — | 31 Dec 2025 | |
| Jane A. Gross |
3/4/5
|
Director |
—
mixed-class rows
|
59,750
mixed-class rows
|
$39,000 | — | 01 May 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.05%
|
46,233
|
$36,205 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.05%
|
46,126
|
$36,000 | — | 31 Dec 2025 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.04%
|
41,844
|
$32,768 | — | 31 Dec 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.04%
|
39,006
|
$30,546 | — | 31 Dec 2025 | |
| SEI INVESTMENTS CO |
13F
|
Company |
0.03%
|
33,829
|
$26,491 | — | 31 Dec 2025 | |
| INTECH INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.03%
|
31,774
|
$24,882 | — | 31 Dec 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.03%
|
30,100
|
$23,571 | — | 31 Dec 2025 | |
| Rockefeller Capital Management L.P. |
13F
|
Company |
0.03%
|
28,118
|
$22,019 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for aTYR PHARMA INC
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sanjay Shukla | ATYR | Common Stock | Sale | -2.38% | $3,655 | $0.9760 | -3,745 | 153,553 | 04 Feb 2026 | Direct |
| Nancy E. Denyes | ATYR | Common Stock | Sale | -3.26% | $1,091 | $0.9761 | -1,118 | 33,124 | 04 Feb 2026 | Direct |
| Jill Marie Broadfoot | ATYR | Common Stock | Sale | -4.01% | $1,521 | $0.9760 | -1,558 | 37,296 | 04 Feb 2026 | Direct |
| Sanjay Shukla | ATYR | Common Stock | Options Exercise | 7.06% | 10,375 | 157,298 | 03 Feb 2026 | Direct | ||
| Sanjay Shukla | ATYR | Restricted Stock Unit | Options Exercise | -100% | -10,375 | 0 | 03 Feb 2026 | Direct | ||
| Nancy E. Denyes | ATYR | Common Stock | Options Exercise | 8.52% | 2,687 | 34,242 | 03 Feb 2026 | Direct | ||
| Nancy E. Denyes | ATYR | Restricted Stock Unit | Options Exercise | -100% | -2,687 | 0 | 03 Feb 2026 | Direct | ||
| Jill Marie Broadfoot | ATYR | Common Stock | Options Exercise | 10.7% | 3,750 | 38,854 | 03 Feb 2026 | Direct | ||
| Jill Marie Broadfoot | ATYR | Restricted Stock Unit | Options Exercise | -100% | -3,750 | 0 | 03 Feb 2026 | Direct | ||
| Sanjay Shukla | ATYR | Employee Stock Option (right to buy) | Award | 1,500,000 | 1,500,000 | 09 Jan 2026 | Direct | |||
| Jill Marie Broadfoot | ATYR | Employee Stock Option (right to buy) | Award | 412,500 | 412,500 | 09 Jan 2026 | Direct | |||
| Nancy E. Denyes | ATYR | Employee Stock Options (right to buy) | Award | 412,500 | 412,500 | 09 Jan 2026 | Direct | |||
| Paul Schimmel | ATYR | Common Stock | Purchase | 29% | 317,999 | 1,413,023 | 09 Oct 2025 | See Footnote | ||
| Paul Schimmel | ATYR | Common Stock | Purchase | 165.1% | 682,001 | 1,095,024 | 08 Oct 2025 | See Footnote | ||
| Sara Zaknoen | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 01 May 2025 | Direct | |||
| Paul Schimmel | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 01 May 2025 | Direct | |||
| Svetlana Lucas | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 01 May 2025 | Direct | |||
| Jane A. Gross | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 01 May 2025 | Direct | |||
| Eric Benevich | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 01 May 2025 | Direct | |||
| Timothy Coughlin | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 01 May 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.